A first-in-human trial is now dosing children with KCNT1-related epilepsy using a novel gene-silencing therapy. Servier's S230815 is an antisense oligonucleotide (ASO) delivered directly into the spinal fluid to reduce production of the faulty potassium channel driving seizures. The KANDLE trial enrolls children ages 2–12 and marks the first clinical test of a KCNT1-targeting ASO in this devastating, often treatment-resistant condition.
A first-in-human clinical trial has begun dosing children with one of childhood epilepsy's most severe and drug-resistant forms. Servier's KANDLE trial is testing S230815, an antisense oligonucleotide (ASO) delivered intrathecally — directly into the cerebrospinal fluid — to silence the mutated KCNT1 gene responsible for the condition. KCNT1-related developmental and epileptic encephalopathy (KCNT1-DEE) causes seizures that can begin within days of birth, and many affected children face profound developmental impairment and high mortality.
The phase 1b/2, open-label, dose-escalation study enrolls children ages 2–12 with a confirmed KCNT1 pathogenic variant. Unlike quinidine — the only prior KCNT1-targeted treatment, which blocks the overactive channel but has shown inconsistent results and cardiac risks — S230815 targets the problem at its genetic source by degrading the faulty messenger RNA before the abnormal channel is even made.
Key Takeaways:
Why it matters: KCNT1-DEE is an ultrarare, often catastrophic epilepsy with no approved disease-modifying therapies. KANDLE represents the first clinical attempt to address the condition at its genetic root, offering hope for a population with very few options.
